

## Shionogi Announces the Commencement of its Operations of Shionogi Pharma Co., Ltd.

**OSAKA, Japan., April 1, 2019** - Shionogi & Co., Ltd. (Head Office: Chuo-ku, Osaka, Japan; President & CEO: Isao Teshirogi, Ph.D.; hereinafter, the “Company” or “Shionogi”) established on October 1, 2018 a new wholly owned subsidiary, “Shionogi Pharma Co., Ltd.” (hereinafter, “Shionogi Pharma”), which assumes the manufacturing-related functions of the Shionogi Group, and has prepared for the succession of the manufacture and sales.

We hereby announce that Shionogi Pharma has commenced its operations on April 1, 2019 as scheduled.

### 1. Overview of Shionogi Pharma

Effective April 1, 2019, Shionogi has transferred its pharmaceutical manufacturing business to Shionogi Pharma through an absorption-type company split with the aim of manufacturing new medicines developed by Shionogi at globally competitive prices as part of the “manufacturing” value chain of the Shionogi Group, while maintaining the high quality of those medicines and their stable provision to markets. On the same day, Shionogi Pharma as the successor company completed an absorption-type merger with Shionogi Pharma Chemicals Co., Ltd. and Shionogi Analysis Center Co., Ltd.

Going forward, Shionogi Pharma will provide a wide range of services under contract, such as manufacturing investigational drugs, analyzing pharmaceutical products, and engineering pharmaceuticals, in addition to manufacturing pharmaceuticals under contract by using its know-how and highly specialized knowledge. Through these services, Shionogi Pharma aims not only to contribute to further development of the pharmaceutical industry in Japan, but also to become a technology-oriented manufacturing company that develops and globally provides new manufacturing methods and products by focusing on the development of manufacturing technologies.

1. Company name	Shionogi Pharma Co., Ltd.
2. Business	Manufacture and contract manufacture of pharmaceutical products, etc.
3. Location of Head Office	5-1 Mishima 2-chome, Settsu, Osaka
4. Representative	Ryuichi Kume, President & CEO
5. Capital	90 million yen
6. Number of outstanding shares	400
7. Number of employees	Approx. 1,300
8. Principal shareholders and investment ratio	Shionogi & Co., Ltd.: 100.0%

### 2. Products to be succeeded for manufacture and sale approval

The manufacture and sale approvals for the products mentioned below will be succeeded from Shionogi to Shionogi Pharma sequentially.

Drugs for circulatory diseases	IRTRA Combination Tablets LD/HD, IRBETAN Tablets 50mg/100mg/200mg, FLUITRAN Tablets 1mg/2mg
--------------------------------	---

Drugs for infectious diseases	BAKTAR Combination Tablets, BAKTAR Combination Granules, FLAGYL Oral Tablets 250mg
Topical steroids	ALMETA Ointment, FULMETA Ointment, FULMETA Cream, FULMETA Lotion, RINDERON-DP Ointment, RINDERON-DP Cream, RINDERON-DP Sol, RINDERON-V Ointment 0.12%, RINDERON-V Cream 0.12%, RINDERON-V Lotion, RINDERON-VG Ointment 0.12%, RINDERON-VG Cream 0.12%, RINDERON-VG Lotion, RINDERON-VG Suppository 0.5mg/1.0mg
Steroid drugs for ophthalmology and otology	PREDONINE Ophthalmic Ointment, RINDERON Ophthalmic Solution 0.01%, RINDERON Ophthalmic, Otic and Nasal Solution 0.1%, Eye, Ear RINDERON-A Ointment, Eye, Nose RINDERON-A Solution
Internal steroid drugs	PREDONINE Tablets 5mg, RINDERON Tablets 0.5mg, RINDERON Powder 0.1%, RINDERON Syrup 0.01%
Steroid drugs for injection	PREDONINE for Injection 10mg/20mg/50mg, RINDERON for Injection 2mg [0.4%]/4mg [0.4%]/20mg [0.4%], RINDERON for Injection 20mg [2%]/100mg [2%], RINDERON for Suspended Injection
Other drugs including those for common colds and analgesics	SG Combination Granules, PL Combination Granules, PL Combination Granules for Infants, MEDICON Tablets 15mg, MEDICON Powder 10%, MEDICON Combination Syrup, CINAL Combination Tablets, CINAL Combination Granules
Medical opioids	MS Contin Tablets 10mg/30mg/60mg OxyContin Tablets 5mg/10mg/20mg/40mg* OxyContin TR Tablets 5mg/10mg/20mg/40mg Oxinorm Powder 2.5mg/5mg/10mg/20mg Oxifast 10mg/50mg Morphine Hydrochloride Injection Solution “Shionogi” 10mg/50mg/200mg

\* Drugs for inventory sales

### 3. Human resources management

Shionogi Pharma also announces new personnel assignment effective April 1, 2019 as follows.

Directors	President	Ryuichi Kume (Senior Executive Officer)
	Executive Vice President	Yoshihiro Furuya
	Director & Senior Executive Officer	Toshio Kawakita
	Director (Part-time)	Noriyuki Kishida (Corporate Officer & Vice President, Human Resources & Administration Dept.)
	Director (Part-time)	Kenji Matsuo (Vice President, Finance & Accounting Dept.)
	Corporate Auditor (Part-time)	Masahiro Fuji (Vice President, Legal Affairs Dept.)
	Corporate Auditor (Part-time)	Hiroki Takagi (Vice President, Internal Control Dept.)
General Managers	Corporate Strategy Dept. & Senior Executive Officer	Harumi Shimazui
	Supply Chain Management Dept. Settsu Plant	Kohei Murashima
	Kanegasaki Plant	Shinji Oda
	Tokushima Plant	Kokichi Kubota
	Quality Control Dept.	Shozo Takechi Makoto Kobayashi

# Press Release



	Production Technology Dept.	Masanori Nishiwaki
	Engineering Technology Dept.	Hiroshi Mitsuyoshi
	General Marketing Compliance Officer	Toshio Kawakita
	Regulatory Affairs Dept.	Keiichi Ueda
	Pharmacovigilance Dept.	Toshihiro Shinosaki
	Quality Assurance Dept.	Tomoki Sogabe

Note: The title in parenthesis after person's name indicates their current post at Shionogi.